SHP681 / Takeda - LARVOL DELTA

Edited transcript of Zeal.Co earnings conference call or presentation (Yahoo Finance) - "We are pleased to share with you today the results of Zealand Pharma's strong start in 2020....Also in the light of -- it seems like Takeda has decided to close down its TAK-681...mentioned the decision by Takeda to close their long-acting GLP-2 program, which was in Phase I. And of course, that we consider that very positive news for Zealand Pharma."

Discontinued • Short Bowel Syndrome

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants (clinicaltrials.gov) - P1; N=102; Completed; Sponsor: Shire; Recruiting ➔ Completed

Clinical • Trial completion